Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NM26
- Development stage
- Discontinued
- Lead developer
- Johnson & Johnson
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
NM26 is a first-in-class investigational bispecific antibody designed to treat atopic dermatitis (AD) by simultaneously targeting two clinically validated pathways involved in the disease. It binds to the interleukin-4 receptor alpha subunit (IL-4Rα), which mediates Th2-driven skin inflammation, and interleukin-31 (IL-31), which is implicated in skin itch and scratching that exacerbate AD symptoms. By blocking both IL-4Rα and IL-31 pathways, NM26 aims to provide improved efficacy over existing therapies that typically target only IL-4/IL-13 signaling. The drug was developed using Numab Therapeutics’ MATCH technology platform for multi-specific antibodies and is currently entering Phase II clinical trials for moderate-to-severe atopic dermatitis. Johnson & Johnson acquired global rights to NM26 through its acquisition of Yellow Jersey Therapeutics, a subsidiary of Numab Therapeutics, with plans to develop it further for AD and potentially other inflammatory skin diseases involving Th2 inflammation and itch.
- Other names
- JNJ 5939JNJ5939JNJ-5939NM 26 2198NM26 2198NM-26 2198NM-26NM26NM 26
02
Targets
IL31 (IL-31)IL4R (Interleukin-4 receptor alpha subunit)
Beyond the preview
Go deeper on NM26.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NM26.